Question 1

What is ResMed's P/E ratio?

Accepted Answer

ResMed (RMD) P/E ratio is 18.7× as of July 22, 2026. The ratio is calculated by dividing market capitalisation by trailing twelve-month earnings (net income), using USD-normalised financials (IAS 21 exchange-rate translation for non-USD reporters).

Question 2

How is the P/E ratio calculated?

Accepted Answer

P/E = Share Price ÷ Trailing Twelve-Month (TTM) Diluted EPS, or equivalently Market Capitalisation ÷ TTM Net Income. All inputs are sourced from audited GAAP/IFRS filings and translated to USD using period-end exchange rates so the multiple is comparable across companies and currencies.

Question 3

What is the P/E ratio?

Accepted Answer

The price-to-earnings (P/E) ratio, also called the earnings multiple, measures how much investors pay per dollar of a company's trailing twelve-month (TTM) earnings. It is calculated as share price ÷ TTM diluted EPS (equivalent to market capitalisation ÷ TTM net income). A higher P/E implies the market is pricing in stronger future earnings growth or lower risk; a lower P/E can signal slower expected growth, higher risk, or potential undervaluation.

Question 4

What is a good P/E ratio for ResMed?

Accepted Answer

There is no universal "good" P/E. As a rule of thumb, the S&P 500 has historically averaged a P/E in the mid-to-high teens; mature, slow-growth businesses commonly trade in the 10–18× range, while high-growth or asset-light companies often trade at 25–50×+. What matters is the comparison to sector peers and to the company's own historical range. For ResMed specifically, the relevant sector benchmark is the current sector median of 24.2×.

Question 5

Is ResMed's P/E ratio high or low?

Accepted Answer

ResMed's P/E ratio of 18.7× is below its own 5-year average of 37.7× and below the sector median of 24.2×. That places the current reading at the 1th percentile of its 10-year history. A higher multiple usually reflects stronger expected growth, lower perceived risk, or higher returns on capital; a lower multiple reflects the opposite.

Question 6

What is ResMed's historical P/E ratio range?

Accepted Answer

In the available daily series, ResMed (RMD) P/E ratio has ranged from a low of 16.5× in 2011 to a high of 91.8× in 2021. The 5-year average is 37.7× and the 5-year median is 30.6×.

Question 7

What was ResMed's P/E ratio in 2025?

Accepted Answer

ResMed (RMD) P/E ratio at the end of 2025 was 27.0×. Annual values reflect the multiple on the last trading day of each calendar year, using the trailing twelve-month earnings figure available at that date.

Question 8

Why does ResMed's P/E ratio change over time?

Accepted Answer

Valuation multiples move with two inputs: the numerator (market capitalisation, which tracks the share price) and the denominator (earnings). Share-price changes — driven by interest rates, earnings expectations, risk appetite, and broader market sentiment — typically dominate short-term moves, while changes in the underlying fundamental drive the longer-term trend. As a result, the ratio can rise during stock-price rallies even if the business itself has not become more valuable, and fall during sell-offs even when fundamentals are improving.


2025	$37.8B	$1.4B	27.0×	+0.1×	Jun 30, 2025
2024	$27.5B	$1.02B	26.9×	-8.9×	Jun 30, 2024
2023	$32.1B	$898M	35.8×	-3.6×	Jun 30, 2023
2022	$30.7B	$779M	39.4×	-36.3×	Jun 30, 2022
2021	$35.9B	$475M	75.6×	+30.9×	Jun 30, 2021
2020	$27.8B	$622M	44.7×	+0.8×	Jun 30, 2020
2019	$17.8B	$405M	43.9×	-3.0×	Jun 30, 2019
2018	$14.8B	$316M	46.9×	+14.6×	Jun 30, 2018
2017	$11.1B	$342M	32.3×	+7.1×	Jun 30, 2017
2016	$8.89B	$352M	25.2×	+2.7×	Jun 30, 2016
2015	$7.94B	$353M	22.5×	+1.9×	Jun 30, 2015
2014	$7.12B	$345M	20.6×	-0.2×	Jun 30, 2014
2013	$6.38B	$307M	20.8×	+3.3×	Jun 30, 2013
2012	$4.45B	$255M	17.5×	-3.3×	Jun 30, 2012
2011	$4.72B	$227M	20.8×	-3.4×	Jun 30, 2011
2010	$4.61B	$190M	24.2×	+3.3×	Jun 30, 2010
2009	$3.07B	$146M	20.9×	-3.6×	Jun 30, 2009
2008	$2.7B	$110M	24.5×	-23.8×	Jun 30, 2008
2007	$3.2B	$66.3M	48.3×	+8.1×	Jun 30, 2007
2006	$3.55B	$88.2M	40.2×	+4.6×	Jun 30, 2006
2005	$2.3B	$64.8M	35.6×	+5.5×	Jun 30, 2005
2004	$1.72B	$57.3M	30.1×	+1.6×	Jun 30, 2004
2003	$1.3B	$45.7M	28.5×	+4.2×	Jun 30, 2003
2002	$911M	$37.5M	24.3×	—	Jun 30, 2002


Agilent Technologies (A)	23.1×
Medtronic (MDT)	22.2×
McKesson (MCK)	22.2×
Illumina (ILMN)	21.7×
GE HealthCare (GEHC)	21.6×
Pfizer (PFE)	21.1×
Quest Diagnostics (DGX)	21.1×
Henry Schein (HSIC)	21.0×
AptarGroup (ATR)	20.9×
IQVIA (IQV)	20.7×
Biogen (BIIB)	19.7×
Zoetis (ZTS)	18.9×
Gilead Sciences (GILD)	18.8×
Humana (HUM)	18.5×
Regeneron Pharmaceuticals (REGN)	18.2×
Bristol-Myers Squibb (BMY)	17.0×
Elevance Health (ELV)	17.0×
HCA Healthcare (HCA)	15.8×
AstraZeneca (AZN)	14.7×
DaVita (DVA)	13.3×
Incyte (INCY)	13.1×
Cigna (CI)	11.1×
Novo Nordisk (NVO)	8.6×
Solventum (SOLV)	7.9×
Universal Health Services (UHS)	7.2×

P/E Ratio for ResMed (RMD) 2002-2026

P/E Ratio daily chart for ResMed (RMD)

Historical P/E Ratio for ResMed (RMD) from 2002 to 2025

About P/E Ratio at ResMed (RMD)

ResMed P/E Ratio by Year

ResMed P/E Ratio 2025: 27.0×

ResMed P/E Ratio 2024: 26.9×

ResMed P/E Ratio 2023: 35.8×

ResMed P/E Ratio 2022: 39.4×

ResMed P/E Ratio 2021: 75.6×

Sector peers by P/E Ratio — chart

Sector peers by P/E Ratio — table

Frequently asked questions

ResMed (RMD) Key Financials